Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-07-26
2011-07-26
Landsman, Robert (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120
Reexamination Certificate
active
07985558
ABSTRACT:
This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
REFERENCES:
patent: 5217899 (1993-06-01), Shapiro et al.
patent: 5348879 (1994-09-01), Shapiro et al.
patent: 5786163 (1998-07-01), Hall
patent: 6040147 (2000-03-01), Ridker et al.
patent: 6288218 (2001-09-01), Levinson
patent: 6323334 (2001-11-01), Kingsbury et al.
patent: 6905827 (2005-06-01), Wohlgemuth et al.
patent: 7087396 (2006-08-01), Tominaga et al.
patent: 7432060 (2008-10-01), Lee
patent: 2002/0072674 (2002-06-01), Criton et al.
patent: 2003/0228570 (2003-12-01), Yat Wah Tom et al.
patent: 2004/0048286 (2004-03-01), Lee
patent: 2007/0042978 (2007-02-01), Girard et al.
patent: 1731910 (2006-12-01), None
patent: 6178687 (1994-06-01), None
patent: 7031479 (1995-02-01), None
patent: 98/07754 (1998-02-01), None
patent: 98/38311 (1998-09-01), None
patent: 99/34217 (1999-07-01), None
patent: 00/35473 (2000-06-01), None
patent: 00/35951 (2000-06-01), None
patent: 00/73498 (2000-12-01), None
patent: 01/70817 (2001-09-01), None
patent: 02/38794 (2002-05-01), None
patent: 2003/094856 (2003-11-01), None
patent: 2004/056868 (2004-07-01), None
patent: 2005/041893 (2005-05-01), None
patent: 2007/130627 (2007-11-01), None
U.S. Appl. No. 09/934,249, filed Aug. 21, 2001, Lee et al.
U.S. Appl. No. 11/800,405, filed May 4, 2007, Lee et al.
U.S. Appl. No. 10/435,482, filed May 9, 2003, Lee et al.
Albert et al., Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. Jun. 4, 2002;105(22):2595-9.
Amendment filed in Response on Jan. 18, 2007 for U.S. Appl. No. 10/435,482.
Anwaruddin et al., “Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study,” J. Am. Coll. Cardiol., 47(1):91-97 (2006).
Auer et al, “C-reactive protein and coronary artery disease,” Jpn Heart J., 43(6):607-619 (2002).
Aukrust et al., “Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy,” Am J Cardiol., 83(3):376-382 (1999).
Baggish et al., “A validated clinical and biochemical score for the diagnosis of acute heart failure: The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score,” Am. Heart J. 151:48-54 (2006).
Baumgarten et al., “Cytokines as emerging targets in the treatment of heart failure,” Trends Cardiovasc Med., 10(5):216-223 (2000).
Bayés-Genís Antoni, “The circulating NTproBNP level, a new biomarker for the diagnosis of heart failure in patients with acute shortness of breath,” Revista Espa{hacek over (n)}ola de Cardiología, 58(10):1142-1144 (2005).
Belch et al., “Oxygen free radicals and congestive heart failure,” Br Heart J., 65(5):245-248 (1991).
Blum et al., “Pathophysiological role of cytokines in congestive heart failure,” Annu. Rev. Med., 52:15-27 (2001) (abstract).
Brint et al., “ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance,” Nat. Immunol., 5(4):373-379 (2004).
Brown, “Techniques for Mechanical Stimulation of cells in vitro: a review,” Journal of Biomechanics, 33:3-14 (2000).
Bruneau, “Selective changes in natriuretic peptide and early response gene expression in isolated rat atria following stimulation by stretch or endothelin-1,” Cardiovasc. Res., 28(10):1519-1525 (1994).
Brunner et al., “Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma,” Intensive Care Med., 30(7):1468-1473 (2004).
Carter et al., “Regulation of ST2L expression of T helper (Th) type 2 cells,” Eur. J. Immunol., 31(10):2979-2985 (2001). (Abstract Only).
Chan et al., “Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes,” J Immunol., 167(3):1238-1244 (2001). (abstract).
Cheng et al., Mechanical strain tightly controls fibroblast growth factor-2 release from cultured human vascular smooth muscle cells. Circ Res. Jan. 1997;80(I):28-36. (Abstract).
Conklin, B. “B-type Natriuretic Peptide: A New Measurement to Distinguish Cardiac From Pulmonary Causes of Acute Dyspenea,” Journal of Emergency Nursing, 31(1):73-75 (2005).
Coyle et al., “Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses,” J Exp Med., 190(7):895-902 (1999).
De Keulenaer et al., “Identification of IEX-1 as a biomechanically controlled nuclear factor-kappaB target gene that inhibits cardiomyocyte hypertrophy,” Circ Res., 90(6):690-696 (2002).
EP 03728848.7 Dec. 15, 2005 Supplementary European Search Report.
Feldman et al., “C-reactive protein is an independent predictor of mortality in women with HIV-1 infection,” J. Acquir. Immune Defic. Syndr., 32(2):210-214 (2003). (abstract).
Forssmann et al., “The heart is the center of a new endocrine, paracrine, and neuroendocrine system,” Arch. Histol. Cytol., 52 Supp1:293-315 (1989). (Abstract).
Frangogiannis et al., “Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion,” Circulation., 98(7):699-710 (1998).
Galvani et al., “Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina,” Circulation, 95(8):2053-2059 (1997). (Abstract).
GenBank Submission; NIH/NCBI; Accession No. AB022176 (PRI Sep. 15, 2007).
GenBank Submission; NIH/NCBI; Accession No. AB024518 (PRI Mar. 10, 1999).
GenBank Submission; NIH/NCBI; Accession No. AL117622 (printed Sep. 25, 2007) (2 pages).
GenBank Submission; NIH/NCBI; Accession No. D12763 (PRI Jan. 23, 2003).
GenBank Submission; NIH/NCBI; Accession No. E07714 (PAT Nov. 4, 2005).
GenBank Submission; NIH/NCBI; Accession No. E07716 (PAT Nov. 4, 2005).
GenBank Submission; NIH/NCBI; Accession No. E08652 (PAT Nov. 4, 2005).
GenBank Submission; NIH/NCBI; Accession No. U04317 (printed Aug. 23, 2000) (2 pages).
GenBank Submission; NIH/NCBI; Accession No. U04319 (printed Aug. 23, 2000) (2 pages).
GenBank Submission; NIH/NCBI; Accession No. X60184 (printed Sep. 25, 2007) (5 pages).
Goetze et al., “B-type natriuretic peptide and its precursor in cardiac venous blood from failing hearts,” European Journal of Heart Failure, 7(1):69-74 (2005).
Gutstein et al., Role of inositol 1,4,5-trisphosphate receptors in regulating apoptotic signaling and heart failure. Heart Vessels. 1997;Suppl 12:53-7.
Gwechenberger et al., Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation. Feb. 2, 1999;99(4):546-51.
Hanyu T, et al. Urinary Thrombomodulin in Patients with Rheumatoid Arthritis: Relationship to Disease Subset. 1999; 18:385-9.
Heeschen et al., Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina Refractory to standard treatment trial. J Am Coll Cardiol. May 2000;35(6):1535-42. Abstract Only.
Hirota et al., Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. Apr. 16, 1999;97(2):189-98.
Interview Summary mailed Nov. 23, 2005 for U.S. Appl. No. 10/024,607.
Invitation to Pay Additional Fees as issued in PCT/US01/46816 on Feb. 19, 2003.
IPER as issued in PCT/US01/46816 on Aug. 12, 2004.
ISR as issued in PCT/US
Fish & Richardson P.C.
Hissong Bruce D
Landsman Robert
The Brigham and Women's Hospital, Inc.
LandOfFree
Methods for diagnosis of cardiovascular disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for diagnosis of cardiovascular disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosis of cardiovascular disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2734205